Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 1;13:847605. doi: 10.3389/fphar.2022.847605

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Liu, Wang, Gu, Che, Wang, Cheng, Yuan, Cheng and Liao.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

KPT-8602 inhibits LPS-induced high expression of pro-inflammatory cytokines in macrophages. (A) Structure of KPT-8602. (B) iBMDMs were treated with various doses of KPT-8602 for 6 h, and cell viability was assessed by the CCK-8 assay kit. (C) Working model of LPS-induced inflammation. (D–G) iBMDMs were pretreated with KPT-8602 at different concentrations and stimulated with LPS for 6 h, and then the mRNA levels of IL-1β (D), IL-6 (E), TNF-α (F), and Nlrp3 (G) were analyzed by real-time PCR. (H–J) Primary peritoneal macrophages (PMs) pretreated with KPT-8602 (5 μM) were treated with LPS for 6 h, and then the mRNA levels of Nlrp3 (H), IL-1β (I), and TNF-α (J) were analyzed by real-time PCR. (^** indicates p < 0.01, ^*** indicates p < 0.001, ^**** indicates p < 0.0001 by one-way ANOVA). n. s. no significant, NT, no treatment.